Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
The RPS and the CMHP have written to the CMA as part of a consultation regarding the supply of Priadel, the lithium medication used by bipolar patients.
The Competitions and Market Authority (CMA) is consulting on proposed commitments from Essential Pharma
Pharmacists, GPs, Psychiatrists and patients are urging Secretary of State for Health and Social Care to ensure a brand of lithium remains available.